Yifan Xinfu Pharmaceutical Co Ltd (002019) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Yifan Xinfu Pharmaceutical Co Ltd (002019) has a cash flow conversion efficiency ratio of 0.005x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥40.18 Million ≈ $5.88 Million USD) by net assets (CN¥8.71 Billion ≈ $1.27 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Yifan Xinfu Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Yifan Xinfu Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Yifan Xinfu Pharmaceutical Co Ltd (002019) financial obligations for a breakdown of total debt and financial obligations.
Yifan Xinfu Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Yifan Xinfu Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Worthington Steel Inc
NYSE:WS
|
0.074x |
|
Aarti Industries Limited
NSE:AARTIIND
|
0.098x |
|
Gränges AB (publ)
ST:GRNG
|
0.013x |
|
Stora Enso Oyj A
HE:STEAV
|
0.007x |
|
RLX TECH. SP.ADR/1 CL.A
F:3CM
|
N/A |
|
LeMaitre Vascular Inc
NASDAQ:LMAT
|
0.076x |
|
BaoViet Holdings
VN:BVH
|
-0.311x |
|
Werner Enterprises Inc
NASDAQ:WERN
|
0.032x |
Annual Cash Flow Conversion Efficiency for Yifan Xinfu Pharmaceutical Co Ltd (2003–2024)
The table below shows the annual cash flow conversion efficiency of Yifan Xinfu Pharmaceutical Co Ltd from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see 002019 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥8.43 Billion ≈ $1.23 Billion |
CN¥640.73 Million ≈ $93.76 Million |
0.076x | +80.06% |
| 2023-12-31 | CN¥8.25 Billion ≈ $1.21 Billion |
CN¥348.58 Million ≈ $51.01 Million |
0.042x | -18.18% |
| 2022-12-31 | CN¥9.15 Billion ≈ $1.34 Billion |
CN¥472.07 Million ≈ $69.08 Million |
0.052x | +50.34% |
| 2021-12-31 | CN¥8.78 Billion ≈ $1.28 Billion |
CN¥301.23 Million ≈ $44.08 Million |
0.034x | -73.01% |
| 2020-12-31 | CN¥8.72 Billion ≈ $1.28 Billion |
CN¥1.11 Billion ≈ $162.21 Million |
0.127x | +6.13% |
| 2019-12-31 | CN¥7.82 Billion ≈ $1.14 Billion |
CN¥937.24 Million ≈ $137.15 Million |
0.120x | -29.51% |
| 2018-12-31 | CN¥6.89 Billion ≈ $1.01 Billion |
CN¥1.17 Billion ≈ $171.34 Million |
0.170x | +1.79% |
| 2017-12-31 | CN¥6.78 Billion ≈ $992.46 Million |
CN¥1.13 Billion ≈ $165.75 Million |
0.167x | -23.88% |
| 2016-12-31 | CN¥3.90 Billion ≈ $570.77 Million |
CN¥855.85 Million ≈ $125.24 Million |
0.219x | +57.24% |
| 2015-12-31 | CN¥2.88 Billion ≈ $421.52 Million |
CN¥401.96 Million ≈ $58.82 Million |
0.140x | +154.00% |
| 2014-12-31 | CN¥2.54 Billion ≈ $372.19 Million |
CN¥139.74 Million ≈ $20.45 Million |
0.055x | -38.38% |
| 2013-12-31 | CN¥384.95 Million ≈ $56.33 Million |
CN¥34.32 Million ≈ $5.02 Million |
0.089x | +43.45% |
| 2012-12-31 | CN¥480.81 Million ≈ $70.36 Million |
CN¥29.88 Million ≈ $4.37 Million |
0.062x | +155.24% |
| 2011-12-31 | CN¥469.52 Million ≈ $68.71 Million |
CN¥-52.82 Million ≈ $-7.73 Million |
-0.113x | -134.03% |
| 2010-12-31 | CN¥703.64 Million ≈ $102.96 Million |
CN¥-33.82 Million ≈ $-4.95 Million |
-0.048x | -174.89% |
| 2009-12-31 | CN¥913.15 Million ≈ $133.62 Million |
CN¥58.61 Million ≈ $8.58 Million |
0.064x | -56.02% |
| 2008-12-31 | CN¥570.87 Million ≈ $83.54 Million |
CN¥83.31 Million ≈ $12.19 Million |
0.146x | -67.81% |
| 2007-12-31 | CN¥548.55 Million ≈ $80.27 Million |
CN¥248.71 Million ≈ $36.39 Million |
0.453x | +351.02% |
| 2006-12-31 | CN¥324.46 Million ≈ $47.48 Million |
CN¥32.62 Million ≈ $4.77 Million |
0.101x | +33.73% |
| 2005-12-31 | CN¥320.93 Million ≈ $46.96 Million |
CN¥24.12 Million ≈ $3.53 Million |
0.075x | -30.63% |
| 2004-12-31 | CN¥309.98 Million ≈ $45.36 Million |
CN¥33.59 Million ≈ $4.91 Million |
0.108x | -19.25% |
| 2003-12-31 | CN¥94.31 Million ≈ $13.80 Million |
CN¥12.65 Million ≈ $1.85 Million |
0.134x | -- |
About Yifan Xinfu Pharmaceutical Co Ltd
Yifan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products, raw materials, and polymer materials in Southeast Asia, Europe and North America, Singapore, South Korea, Italy, China, Germany, and the United States. It offers Chinese patent medicines, chemical medicines and biological medicines; and vitamin products, including vitamin B5 an… Read more